Is it time to Buy before this week’s earning report NASDAQ:PASG, NASDAQ:ADMS, NASDAQ:LSXMB, NASDAQ:BWEN

0
44

PASSAGE BIO (NASDAQ:PASG) EARNINGS INFORMATION (NASDAQ:PASG)

Passage Bio last announced its quarterly earnings results on August 5th, 2021. The reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by $0.17. Passage Bio has generated ($2.91) earnings per share over the last year (($2.84) diluted earnings per share). Earnings for Passage Bio are expected to grow in the coming year, from ($3.10) to ($2.85) per share. Passage Bio has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

IS PASSAGE BIO A BUY RIGHT NOW? (NASDAQ:PASG)

8 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Passage Bio in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Passage Bio stock.
Passage Bio

ADAMAS PHARMACEUTICALS (NASDAQ:ADMS) EARNINGS INFORMATION (NASDAQ:ADMS)

Adamas Pharmaceuticals last announced its earnings results on May 9th, 2021. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.15. The company had revenue of $19.31 million for the quarter, compared to analysts’ expectations of $19.59 million. Adamas Pharmaceuticals has generated ($2.03) earnings per share over the last year (($1.79) diluted earnings per share). Earnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.05) to ($0.36) per share. Adamas Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Monday, August 9th, 2021. Adamas Pharmaceuticals will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

IS ADAMAS PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:ADMS)

5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Adamas Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Adamas Pharmaceuticals stock.
Adamas Pharmaceuticals

THE LIBERTY SIRIUSXM GROUP (NASDAQ:LSXMB) EARNINGS INFORMATION (NASDAQ:LSXMB)

The Liberty SiriusXM Group last announced its quarterly earnings data on May 7th, 2021. The technology company reported ($0.03) EPS for the quarter. The company had revenue of $2.06 billion for the quarter. The Liberty SiriusXM Group has generated $0.00 earnings per share over the last year (($2.91) diluted earnings per share).

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN THE LIBERTY SIRIUSXM GROUP? (NASDAQ:LSXMB)

Wall Street analysts have given The Liberty SiriusXM Group a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The Liberty SiriusXM Group wasn’t one of them. MarketBeat thinks these five companies may be even better buys.

BROADWIND (NASDAQ:BWEN) EARNINGS INFORMATION (NASDAQ:BWEN)

Broadwind last issued its earnings data on May 6th, 2021. The industrial products company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.10. The firm had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $37.42 million. Broadwind has generated ($0.09) earnings per share over the last year (($0.22) diluted earnings per share). Earnings for Broadwind are expected to grow by 50.00% in the coming year, from $0.08 to $0.12 per share.

IS BROADWIND A BUY RIGHT NOW? (NASDAQ:BWEN)

3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Broadwind in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Broadwind stock.
Broadwind